EUVIMEDEUVIMED entdecken
Crossref

Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial

Zhenyang Liang, Lei Qin, Mian Wang, Xianzhao Wang, Huanyi Zhang, Yin Liu iD, Yan Li, Limin Liu, Jun Luo iD, Songwu Dong iD, Jincheng Guo iD, Hengqing Zhu und 9 weitere

Circulation: Cardiovascular Interventions · 31.10.2026

DOI: 10.1161/circinterventions.126.017029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Interventions, online erschienen am 31.10.2026. Verfasst von Zhenyang Liang und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Nort…. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The BRIGHT-4 trial (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4) demonstrated that procedural anticoagulation with bivalirudin plus a high-dose postprocedure infusion reduced the 30-day composite end point of all-cause death or Bleeding Academic Research Consortium types 3 to 5 bleeding compared with heparin monotherapy in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI) with radial artery access. We now report the 12-month follow-up results to evaluate the long-term outcomes of primary PCI with these 2 anticoagulation regimens. METHODS: In this multicenter, open-label, randomized controlled trial, 6016 patients with ST-segment–elevation myocardial infarction undergoing primary PCI with radial artery access were randomly assigned (1:1) to receive bivalirudin with a high-dose post-PCI infusion for 2 to 4 hours (n=3009) or heparin monotherapy (n=3007). The primary outcome of interest was the composite of all-cause death or Bleeding Academic Research Consortium types 3 to 5 bleeding at 12 months. RESULTS: At 12 months, the primary outcome occurred in 124 (4.1%) patients in the bivalirudin group and 169 (5.6%) patients in the heparin group (hazard ratio, 0.73 [95% CI, 0.58–0.92]; P =0.007). Bivalirudin resulted in lower 12-month rates of Bleeding Academic Research Consortium types 3 to 5 bleeding (0.6% versus 1.2%; hazard ratio, 0.49 [95% CI, 0.28–0.87]; P =0.01) and stent thrombosis (0.8% versus 1.3%; hazard ratio, 0.60 [95% CI, 0.36–0.99]; P =0.045), with nonsignificant differences in all-cause death (3.8% versus 4.8%; hazard ratio, 0.80 [95% CI, 0.63–1.02]; P =0.08), cardiovascular death, reinfarction, ischemia-driven target vessel revascularization, and stroke between the 2 groups. CONCLUSIONS: Among patients with ST-segment–elevation myocardial infarction undergoing primary PCI with radial artery access, the benefits of bivalirudin with a high-dose post-PCI infusion in reducing the composite end point of all-cause death or Bleeding Academic Research Consortium types 3 to 5 bleeding at 30 days compared with heparin monotherapy are maintained through 12-month follow-up. These findings support the use of bivalirudin with a post-PCI high-dose infusion as an alternative to heparin to reduce mortality and major bleeding in patients with ST-segment–elevation myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03822975.

Schlagwörter

Stichwörter der Autor:innen

bleedingheparinischemiamyocardial infarctionpercutaneous coronary intervention

Autor:innen und Institutionen

  • State Key Laboratory of Frigid Zone Cardiovascular Diseases, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (Z.L., M.Q., Yi Li, Y.H.).
  • Department of Cardiology, Kaifeng Central Hospital, China (L.Q.).
  • Department of Cardiology, West China Hospital of Sichuan University, Chengdu (M.W.).
  • Department of Cardiology, Yuzhou City People's Hospital, China (X.W.).
  • Department of Cardiology, Tai'an City Central Hospital, China (H. Zhang).
  • Department of Cardiology, Tianjin Chest Hospital, China (Yin Liu).

ORCID-Profile: Yin Liu, Jun Luo, Songwu Dong, Jincheng Guo, Yi Li, Yaling Han, Gregg W Stone

Zitieren

APA

Liang, Z., Qin, L., Wang, M., Wang, X., Zhang, H., Liu, Y., Li, Y., Liu, L., Luo, J., Dong, S., Guo, J., Zhu, H., Li, S., Zheng, H., Liu, L., Wu, Y., Zhong, Y., Qiu, M., Li, Y., …, & Stone, G. W. (2026). Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.126.017029

Vancouver

Liang Z, Qin L, Wang M, Wang X, Zhang H, Liu Y, et al. Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.126.017029

BibTeX
@article{Liang2026,
  author = {Liang, Zhenyang and Qin, Lei and Wang, Mian and Wang, Xianzhao and Zhang, Huanyi and Liu, Yin and Li, Yan and Liu, Limin and Luo, Jun and Dong, Songwu and Guo, Jincheng and Zhu, Hengqing and Li, Shengli and Zheng, Haijun and Liu, Lijun and Wu, Yanqing and Zhong, Yiming and Qiu, Miaohan and Li, Yi and Han, Yaling and Stone, Gregg W},
  title = {Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.126.017029}
}
Kostenlos starten →